BELLUS Health Inc. (BLU): Price and Financial Metrics
BLU Price/Volume Stats
| Current price | $14.74 | 52-week high | $14.76 |
| Prev. close | $14.74 | 52-week low | $6.38 |
| Day low | $14.74 | Volume | 3,449,200 |
| Day high | $14.75 | Avg. volume | 3,081,445 |
| 50-day MA | $14.55 | Dividend yield | N/A |
| 200-day MA | $10.13 | Market Cap | 1.87B |
BLU Stock Price Chart Interactive Chart >
BELLUS Health Inc. (BLU) Company Bio
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Latest BLU News From Around the Web
Below are the latest news stories about BELLUS HEALTH INC that investors may wish to consider to help them evaluate BLU as an investment opportunity.
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK AcquisitionMONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl |
BELLUS Health Reports First Quarter 2023 Financial Results and Business HighlightsLAVAL, Quebec, May 12, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023. |
GSK Stock: A Value Trap or a Hidden Gem?GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. |
BELLUS Health Announces Meeting UpdatesLAVAL, Quebec, April 26, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 |
Why Shares of Bellus Health Skyrocketed This WeekShares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC). |
BLU Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 0.89% |
| 1-year | 57.65% |
| 3-year | 383.28% |
| 5-year | 435.71% |
| YTD | 79.32% |
| 2022 | 2.11% |
| 2021 | 163.07% |
| 2020 | -59.74% |
| 2019 | 175.96% |
| 2018 | 155.26% |
Loading social stream, please wait...